$ENTX earnings report

Entera reports Q3 2026 net loss of $15.6 million, driven by a $7.5 million non-cash warrant remeasurement, as EB613 Phase 3 preparations advance and cash rose to $265.9 million after a $275.0 million private placement. AlphAI read Entera Bio's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readENTX · Q3 2026 · ended 2026-09-30

Entera reports Q3 2026 net loss of $15.6 million, driven by a $7.5 million non-cash warrant remeasurement, as EB613 Phase 3 preparations advance and cash rose to $265.9 million after a $275.0 million private placement

→Mixed quarter

The company reported no revenue and a larger loss, with the company attributing the increase mainly to a $7.5 million non-cash warrant remeasurement and to Phase 3 start-up and OPKO collaboration activity. Balance sheet strength is substantial, with cash of $265.9 million and a company statement that cash is expected to fund the EB613 Phase 3 program through topline results and NDA submission and operations into 2030. The filing provides no revenue, no guidance and no prior-quarter comparison, so the read rests on clinical progress and the balance sheet.

Revenue
—

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenues, three months ended September 30, 2026GAAP—––
Research and development expenses, three months ended September 30, 2026GAAP$4,925 thousand ($4.9 million in text)–$3.3 million increase (as stated in text)
General and administrative expenses, three months ended September 30, 2026GAAP$2,340 thousand ($2.3 million in text)––
Total operating expenses, three months ended September 30, 2026GAAP$7.26M––
Operating loss, three months ended September 30, 2026GAAP$7.26M––
Financial expenses (income), net, three months ended September 30, 2026GAAP$8.33M––
Net loss, three months ended September 30, 2026GAAP$15,597 thousand ($15.6 million in text)––
Loss per ordinary share, basic and diluted, three months ended September 30, 2026GAAP$0.11––

What drove it

  • R&D expense rose to $4,925 thousand from $1,643 thousand. The company attributes the increase primarily to start-up activities for the EB613 Phase 3 program and to activities under the OPKO collaboration.
  • Company explanation for the higher net loss: a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 and July 2026 private placements, reclassified to equity in August 2026.
  • Financial expenses (income), net moved to $8,332 thousand of expense from $(56) thousand of income in the prior-year quarter. The filing does not break down this line beyond the warrant remeasurement described above.

Concerns

  • No revenue is reported in either period, so the net loss is entirely driven by operating expenses and the financial expense line.
  • The net loss more than quadrupled to $15,597 thousand from $3,200 thousand, and the financial expense line of $8,332 thousand is the largest contributor to the gap between operating loss and net loss.
  • The filing lists the Phase 3 topline readout in the second half of 2028 and the company's Nasdaq listing standards among forward-looking risk factors, which the company names as matters that could affect results.
  • The forward-looking statements section lists ability to continue as a going concern absent access to sources of liquidity as a risk factor, although the company states its cash is expected to fund operations into 2030.

What to watch

  • Timing of first clinical site activation for the EB613 Phase 3 study, which the company expects in late 2026.
  • Topline results from the EB613 Phase 3 study, anticipated in the second half of 2028.
  • Progress on the EB612 Phase 1 single ascending dose study, which the company plans to initiate in 2027.
  • Whether future quarters show a further change in financial expenses, net, following the August 2026 reclassification of the pre-funded warrants to equity.
  • Quarterly cash use against the $265.9 million cash balance, given the company's statement that cash supports operations into 2030.

Balance sheet and cash flow

  • Cash and cash equivalents: $265,883 thousand ($265.9 million) as of September 30, 2026, compared with $7,108 thousand as of December 31, 2025 (audited).
  • Restricted cash: $6,536 thousand ($6.5 million) as of September 30, 2026, primarily designated to fund the OPKO collaboration; $7,775 thousand as of December 31, 2025.
  • Total assets: $277,040 thousand as of September 30, 2026, compared with $15,993 thousand as of December 31, 2025.
  • Total liabilities: $2,758 thousand as of September 30, 2026, compared with $2,892 thousand as of December 31, 2025.
  • Total shareholders' equity: $274,282 thousand as of September 30, 2026, compared with $13,101 thousand as of December 31, 2025.
  • Private placement: in July 2026 the company completed an oversubscribed private placement with gross proceeds of approximately $275.0 million before placement agent fees and offering expenses, led by existing investor BVF Partners L.P.
  • Company statement: cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of EB613 through topline results and the anticipated NDA submission, and to support operations into 2030.
  • Company statement: the net loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 and July 2026 private placements, which were reclassified to equity in August 2026.

Analysis

Entera Bio reported no revenue for the quarter ended September 30, 2026, and a GAAP net loss of $15,597 thousand, or $0.11 per ordinary share, against a net loss of $3,200 thousand, or $0.07 per share, in the same quarter of 2025. Operating expenses rose to $7,265 thousand from $3,256 thousand. Research and development expense was $4,925 thousand against $1,643 thousand, and the company attributes the increase primarily to start-up activities for the EB613 Phase 3 program and to activities under the OPKO collaboration. General and administrative expense was $2,340 thousand against $1,613 thousand. The filing does not print a percentage change for either expense line.

Below operating loss, financial expenses (income), net moved to $8,332 thousand of expense from $(56) thousand of income. The company states that the net loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in its April 2026 and July 2026 private placements, which were reclassified to equity in August 2026. The gap between the $7,265 thousand operating loss and the $15,597 thousand net loss is therefore largely this non-cash item, as the company describes it.

The balance sheet changed substantially. Cash and cash equivalents were $265,883 thousand at September 30, 2026, against $7,108 thousand at December 31, 2025, and restricted cash was $6,536 thousand, primarily designated to fund the OPKO collaboration. Total assets rose to $277,040 thousand from $15,993 thousand, and shareholders' equity to $274,282 thousand from $13,101 thousand. The increase follows the July 2026 private placement, which the company describes as oversubscribed with gross proceeds of approximately $275.0 million before placement agent fees and offering expenses. Total liabilities were $2,758 thousand. The company states that its cash is expected to fully fund the planned EB613 Phase 3 program through topline results and the anticipated NDA submission, and to support operations into 2030.

Operationally, the quarter centred on EB613 Phase 3 preparation. The company reported first clinical site activation expected in late 2026, a Phase 3 design of approximately 900 postmenopausal women randomized 2:1 to EB613 or placebo, and topline results anticipated in the second half of 2028. It also presented a post-hoc Phase 2 analysis at ASBMR 2026 in which bone turnover marker changes were enhanced in women with T-scores of -2.5 or lower. Two board appointments are effective December 1, 2026, and several senior clinical hires were announced. EB612 remains in IND-enabling work with OPKO, with a Phase 1 start planned for 2027.

The filing provides no guidance, no segment data, no cash flow statement and no prior-quarter comparison, so sequential trends cannot be read from the document. The primary figures to monitor are the operating expense run-rate as Phase 3 start-up activity scales, the non-cash financial expense line from the warrant accounting, and cash consumption against the reported balance.

Management, verbatim

The third quarter of 2026 transitioned our expanding team into late-stage clinical execution mode.

Miranda Toledano, Chief Executive Officer

Not in the filing

stated, not guessed
  • No revenue figure is printed beyond the dash shown for revenues, cost of revenues and gross profit; no revenue growth or gross margin can be stated.
  • No prior-year percentage change is printed for research and development, general and administrative, total operating expenses, operating loss, financial expenses, net loss or loss per share.
  • No prior-quarter (Q2 2026) figures are printed in the filing, so no quarter-over-quarter changes are available.
  • No consensus estimates or analyst expectations are in the documents.
  • No cash flow statement is included, so operating cash flow, investing cash flow and free cash flow are not reported.
  • No nine-month or year-to-date columns are printed.
  • No share repurchase or dividend activity is reported.
  • No segment or geographic revenue breakdown is provided.
  • The filing does not break down financial expenses (income), net beyond the warrant remeasurement the company describes as $7.5 million.
  • No share price reaction is included in the documents.
  • The previous outlook covered late 2026 through 2030 and gave no quarterly figures for Q3 2026 to compare with.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readENTX · Second Quarter 2026 · ended June 30, 2026

Entera Announces Second Quarter 2026 Financial Results and Business Updates

✓Solid quarter

The quarter included FDA alignment on the EB613 registrational Phase 3 plan and an oversubscribed private placement providing approximately $275.0 million in gross proceeds, while research and development expense and net loss increased as the company prepared for Phase 3 and advanced the OPKO collaboration.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Cash and cash equivalentsother$11.3M––
Restricted cashother$7.1M––
Research and development expensesother$3.2M––
General and administrative expensesother$1.4M––
Net lossother$7.3M––
Net loss per ordinary share, basic and dilutedother$0.14 per ordinary share (basic and diluted)––

Late 2026 through 2030 outlook

  • NoteEntera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.
  • NoteEntera and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.
  • NoteThe net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through the anticipated submission of NDA to the FDA, advance EB612 into the clinic in collaboration with OPKO and extend the Company’s cash runway into 2030.
  • NoteOn a pro forma basis, following the closing of the July 2026 private placement in which the Company received aggregate gross proceeds of approximately $275.0 million, the Company’s cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of EB613 through topline results and the anticipated submission of an NDA to the FDA and to support the Company’s operations into 2030.

What drove it

  • The FDA accepted Entera’s plan to conduct a single, randomized, double-blind, placebo-controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis to support a potential NDA submission for EB613.
  • Single-tablet EB613 demonstrated a pharmacokinetic and pharmacodynamic profile comparable to multi-tablet EB613 and Forteo® in comparative Phase 1 data presented at ENDO 2026.
  • Research and development expense increased primarily due to increased materials, production and other costs related to preparation of the EB613 Phase 3 program and activities under the OPKO collaboration.
  • EB612 preclinical data across three models showed robust bioavailability and rapid, sustained increases in serum calcium lasting approximately three days.
  • EB618 non-human primate data showed robust bioavailability, dose-proportional systemic exposure and dose-proportional effects on postprandial blood glucose levels.

Concerns

  • Net loss was $7.3 million, compared with $2.7 million for the three months ended June 30, 2025.
  • The increase in net loss was primarily driven by a $2.7 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 private placement and classified as a financial liability.
  • EB613 Phase 3 initiation is planned for late 2026, with topline results anticipated in the second half of 2028.
  • The Company expects to evaluate initiation of EB618 clinical development pursuant to analysis of Phase 1 SAD/MAD studies of subcutaneous injectable OXM being conducted by OPKO.

What to watch

  • Initiation of the EB613 registrational Phase 3 study in late 2026.
  • Topline EB613 Phase 3 results anticipated in the second half of 2028.
  • An IND filing for EB612 intended in the first half of 2027.
  • New Phase 2 analysis of EB613 scheduled for plenary poster presentation at the ASBMR 2026 Annual Meeting taking place October 9–12, 2026.
  • Analysis of OPKO’s Phase 1 SAD/MAD studies of subcutaneous injectable OXM in relation to potential EB618 clinical development.

Balance sheet and cash flow

  • Cash and cash equivalents were $11.3 million as of June 30, 2026.
  • Restricted cash was $7.1 million, primarily designated to fund the OPKO collaboration.
  • Subsequent to quarter end, the July 2026 private placement provided gross proceeds of approximately $275.0 million before deducting placement agent fees and offering expenses.
  • In April 2026, Entera announced a private placement led by BVF for approximately $10.0 million in gross proceeds, with the potential for up to $24.5 million in total proceeds upon full exercise of accompanying five-year warrants.

Analysis

Entera reported a development-focused second quarter marked by regulatory progress and financing rather than commercial performance. The FDA accepted the company’s plan for a single randomized, double-blind, placebo-controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis for EB613. The company plans to initiate the registrational study in late 2026, with topline results anticipated in the second half of 2028. The proposed NDA package is expected to include a scientific bridge analysis with Forteo® under the 505(b)(2) pathway and a transiliac crest bone biopsy sub-study in a subset of patients.

Operating expenses increased as Entera readied EB613 for Phase 3 and worked under the OPKO collaboration. Research and development expenses were $3.2 million, compared with $1.5 million in the prior-year quarter, with the company citing increased materials, production and other preparation costs for the EB613 Phase 3 program as well as OPKO collaboration activities. General and administrative expenses were $1.4 million, compared with $1.1 million. Net loss was $7.3 million, or $0.14 per ordinary share basic and diluted, versus $2.7 million, or $0.06 per ordinary share basic and diluted. Management said the increase was primarily driven by a $2.7 million non-cash fair value remeasurement of pre-funded warrants.

Liquidity changed materially after quarter end. Cash and cash equivalents stood at $11.3 million at June 30, 2026, with $7.1 million of restricted cash primarily designated for the OPKO collaboration. In July 2026, Entera announced an oversubscribed private placement providing gross proceeds of approximately $275.0 million before fees and expenses. The company stated that the net proceeds are anticipated to support the EB613 Phase 3 registrational program through anticipated NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030.

Pipeline execution remains the central determinant of the next stages. Single-tablet EB613 Phase 1 data presented at ENDO 2026 were described as comparable with multi-tablet EB613 and Forteo® on pharmacokinetic and pharmacodynamic profiles. EB612 remains in IND-enabling work, with Entera and OPKO intending to file an IND in the first half of 2027. EB618 produced preclinical non-human primate PK/PD data, but the company expects to evaluate clinical initiation based on analysis of OPKO’s Phase 1 SAD/MAD studies of subcutaneous injectable OXM.

The key near-term items are the planned EB613 Phase 3 initiation in late 2026, the EB612 IND timing in the first half of 2027, and further EB613 data presentation at ASBMR 2026. The filing provides no revenue, margin, operating-income, cash-flow, debt, or revenue guidance figures, consistent with the company’s clinical-stage profile.

Management, verbatim

The capital raising transaction we announced on July 27, 2026, led by BVF is transformational for Entera.

Miranda Toledano, Chief Executive Officer of Entera

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue by segment
  • Gross profit and gross margin
  • Operating income or loss
  • Non-GAAP operating income or loss
  • Non-GAAP net income or loss
  • Non-GAAP EPS
  • Operating cash flow
  • Free cash flow
  • Debt
  • Share repurchases
  • Dividends
  • Capital expenditures
  • Prior-quarter comparisons for reported financial metrics
  • Revenue guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Previous-quarter outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ENTX earnings dates

When is Entera Bio's next earnings date?
AlphAI has no date for ENTX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.